Please assess the completion status of the following clinical trial:

Trial Title: Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* acute migraine as per ICHD-II criteria~* pediatric (age 10-18)~Exclusion Criteria:~For Valproic Acid (VPA)~* Pregnancy~* Liver disease (Acute or Chronic)~* Urea Cycle Disorder~* Mitochondrial Disease~For Dihydroergotamine (DHE)~* Pregnancy~* Peripheral vascular disease, coronary heart disease~* History of cerebrovascular event~* Severe or poorly controlled hypertension~* Impaired liver or renal function~* Triptan given in last 24 hours~* Hemiplegic migraine

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Cross-Over to Dihydroergotamine (Type: ACTIVE_COMPARATOR): An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose \>1mg and not exceeding 3mg over 24 hours.
- Cross-Over to Valproic Acid (Type: ACTIVE_COMPARATOR): Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose \>1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
- Valproic Acid (Type: ACTIVE_COMPARATOR): An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
- Dihydroergotamine (Type: ACTIVE_COMPARATOR): Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose \>1mg and not exceeding 3mg over 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).